ArticleHypertension (Dallas, Tex. : 1979)2026
Inhibition of ROCK2 via KD025/Belumosudil Alleviates Hypertensive End-Organ Damage.
Daniel J Fehrenbach, C Duncan Smart, Jean W Wassenaar, Sharia Yasmin, Xinlan L Li, Marisa N Sepulveda, Ariane Imulinde Sugi, Hiroaki Shimokawa, Amanda C Doran, Il-Man Kim and 1 more
Abstract read
In one paragraphArticle in Hypertension (Dallas, Tex. : 1979), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Daniel J FehrenbachDivision of Clinical Pharmacology, Department of Medicine (D.J.F., X.L.L., A.I.S., M.S.M.), Indiana University School of Medicine, Indianapolis.ORCID 0000-0003-3382-464X C Duncan SmartDepartment of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN (C.D.S., M.S.M.).ORCID 0000-0003-0391-3916 Jean W WassenaarDivision of Cardiovascular Medicine, Department of Medicine (J.W.W., A.C.D., M.S.M.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-2835-6338 Sharia YasminDivision of Clinical Pharmacology, Department of Medicine (D.J.F., S.Y., M.S.M.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-8452-405X Xinlan L LiDivision of Clinical Pharmacology, Department of Medicine (D.J.F., X.L.L., A.I.S., M.S.M.), Indiana University School of Medicine, Indianapolis.
Marisa N SepulvedaDepartment of Anatomy, Cell Biology, and Physiology (M.N.S., I.-m.K., M.S.M.), Indiana University School of Medicine, Indianapolis.ORCID 0000-0003-3486-9508 Ariane Imulinde SugiDivision of Clinical Pharmacology, Department of Medicine (D.J.F., X.L.L., A.I.S., M.S.M.), Indiana University School of Medicine, Indianapolis.
Amanda C DoranDivision of Cardiovascular Medicine, Department of Medicine (J.W.W., A.C.D., M.S.M.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-1576-6274 Il-Man KimDepartment of Anatomy, Cell Biology, and Physiology (M.N.S., I.-m.K., M.S.M.), Indiana University School of Medicine, Indianapolis.ORCID 0000-0002-9268-8337 Meena S MadhurDivision of Clinical Pharmacology, Department of Medicine (D.J.F., X.L.L., A.I.S., M.S.M.), Indiana University School of Medicine, Indianapolis.ORCID 0000-0002-0407-634X Funding
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3MCLINICAL PHARMACOLOGY TRAINING PROGRAMT32GM007569 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Bjorn C Knollmann · 1985 to 2026
$12.4MImmunophenotyping of Human Hypertension Using Single Cell Multiplex Mass Cytometry to Identify Novel Therapeutic TargetsDP2HL137166 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MADHUR, MEENAKSHI SWAMINATHAN · 2016 to 2021
$2.8MImmune Modulation in HypertensionR01HL161212 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MADHUR, MEENAKSHI SWAMINATHAN · 2022 to 2025
$2.4MHypertension-associated Trained Immunity in Myeloid Cells is a Determinant of AtherosclerosisR01HL174961 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JONATHAN David BROWN, AMANDA C DORAN · 2025 to 2026
$1.5MDeciphering the novel regulatory mechanisms of neovascularization, cardiomyocyte survival, and endothelial cell-cardiomyocyte crosstalk in myocardial infarctionR01HL180692 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI Il-man Kim · 2025 to 2026
$1.3MNovel role of ROCK2 in Immune Mechanisms of Takotsubo CardiomyopathyK99HL177309 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI Daniel J Fehrenbach · 2025 to 2026
$248kInterleukin-21 and endothelial dysfunction in hypertensionF30HL151069 · NHLBI · VANDERBILT UNIVERSITY · PI SMART, CHARLES DUNCAN · 2020 to 2023
$140kNHLBI NIH HHS DP2 HL137166NHLBI NIH HHS F30 HL151069NHLBI NIH HHS K99 HL177309NHLBI NIH HHS R01 HL161212NHLBI NIH HHS R01 HL174961NHLBI NIH HHS R01 HL180692NIGMS NIH HHS T32 GM007347NIGMS NIH HHS T32 GM007569
6 · The paper itselfAbstract
backgroundDespite achieving target blood pressure, hypertensive individuals have an elevated risk of cardiovascular disease, likely due to unresolved inflammation. Thus, adjunctive immune-modulating therapies are needed to protect patients with hypertension from end-organ damage. We previously showed that T helper 17 cells, which produce the proinflammatory cytokine IL (interleukin)-17A, contribute to hypertensive tissue injury. ROCK2 (Rho-associated coiled-coil-containing protein kinase 2) is a molecular switch governing T helper cell differentiation by promoting T helper 17 polarization and inhibiting T regulatory cell polarization. The present study tests whether T-cell-specific deletion of
methodsT-cell-specific
resultsT-cell-specific
conclusionsROCK2 inhibition may serve as an adjunct immune-modulating therapy to mitigate the end-organ damage that occurs in the heart, vasculature, and kidney in hypertension.
Indexed as
blood pressurefibrosishypertensioninterleukinrisk factors
Identifiers
PMID42836284
PMCPMC13644852
What Socratic holds
Textmetadata
Read underepoch 390